title: Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall.
abstract: OBJECTIVE
  To study the impact of dose fractionation of adjuvant radiation therapy (RT) on local recurrence (LR) and the relation of LR to radiation fields.
  
  
  METHODS
  LR rates were analyzed in 462 adult patients with soft tissue sarcoma who underwent surgical excision and adjuvant RT at five Scandinavian sarcoma centers from 1998 to 2009. Medical records were reviewed for dose fractionation parameters and to determine the location of the LR relative to the radiation portals.
  
  
  RESULTS
  Fifty-five of 462 patients developed a LR (11.9%). Negative prognostic factors included intralesional surgical margin (hazard ratio [HR]: 7.83, 95% confidence interval [CI]: 3.08-20.0), high malignancy grade (HR: 5.82, 95% CI: 1.31-25.8), age at diagnosis (HR per 10 years: 1.27, 95% CI: 1.03-1.56), and malignant peripheral nerve sheath tumor histological subtype (HR: 6.66, 95% CI: 2.56-17.3). RT dose was tailored to margin status. No correlation between RT dose and LR rate was found in multiple Cox regression analysis. The majority (65%) of LRs occurred within the primary RT volume.
  
  
  CONCLUSIONS
  No significant dose-response effect of adjuvant RT was demonstrated. Interestingly, patients given 45-Gy accelerated RT (1.8 Gy twice daily/2.5 weeks) had the best local outcome. A total dose of 50 Gy in 25 fractions seemed adequate following wide margin surgery. The risk of LR was associated with histopathologic subtype, which should be included in the treatment algorithm of adjuvant RT in soft tissue sarcoma.
authors.affiliation: Department of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway. nina.louise.jebsen@helse-bergen.no
authors.forename: Nina L
authors.initials: NL
authors.lastname: Jebsen
authors.forename: Jacob
authors.initials: J
authors.lastname: Engellau
authors.forename: Katarina
authors.initials: K
authors.lastname: Engström
authors.forename: Henrik C
authors.initials: HC
authors.lastname: Bauer
authors.forename: Odd R
authors.initials: OR
authors.lastname: Monge
authors.forename: Ludvig P
authors.initials: LP
authors.lastname: Muren
authors.forename: Geir E
authors.initials: GE
authors.lastname: Eide
authors.forename: Clement S
authors.initials: CS
authors.lastname: Trovik
authors.forename: Oyvind S
authors.initials: OS
authors.lastname: Bruland
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019583:Dose Fractionation, Radiation; D004317:Doxorubicin / Q000008:administration & dosage; D005121:Extremities; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D018714:Radiotherapy, Adjuvant; D012509:Sarcoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D016019:Survival Analysis; D060726:Torso; D055815:Young Adult
chemical_list: D004317:Doxorubicin; D007069:Ifosfamide